Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Fatima Ghamlouche

Showing results (1-10 of 7) with videos related to

Pageof 1
Sort By:
Methods in Molecular Biology (Clifton, N.J.)|March 13, 2024
Prostate Cancer Organoids for Tumor Modeling and Drug ScreeningAmani Yehya, Fatima Ghamlouche, Sana Hachem, et al.
Cancer Drug Resistance (Alhambra, Calif.)|September 30, 2022
Drug resistance in metastatic castration-resistant prostate cancer: an update on the status quoAmani Yehya, Fatima Ghamlouche, Amin Zahwe, et al.
International Journal of Molecular Sciences|May 27, 2026
Integrated Phenotypic and Transcriptomic Profiling Positions ONC212 as a Lead Imipridone in Androgen-Independent Prostate Cancer ModelsFatima Ghamlouche, Amani Yehya, Abdallah Kurdi, et al.
World Journal of Clinical Oncology|January 2, 2026
Liquid biopsy in genitourinary cancers: Diagnostic and prognostic implicationsJoe Youssef, Amani Yehya, Zahraa Salhab, et al.
Frontiers in Cell and Developmental Biology|July 16, 2025
Repurposing piroxicam enhances the antineoplastic effects of docetaxel and enzalutamide in prostate cancer cells using 2D and 3D <i>in vitro</i> culture modelsAmani Yehya, Fatima Ghamlouche, Raed Karami, et al.
Translational Oncology|January 6, 2023
MicroRNAs as clinical tools for diagnosis, prognosis, and therapy in prostate cancerFatima Ghamlouche, Amani Yehya, Yousef Zeid, et al.
Pharmacological Reports : PR|November 17, 2024
ONC206, an imipridone derivative, demonstrates anti-colorectal cancer activity against stem/progenitor cells in 3D cell cultures and in patient-derived organoidsAlissar Monzer, Fatima Ghamlouche, Kevork Wakimian, et al.
Pageof 1

Showing results (1-10 of 7) with videos related to

Sort By:
Pageof 1
Methods in Molecular Biology (Clifton, N.J.)|March 13, 2024
Prostate Cancer Organoids for Tumor Modeling and Drug ScreeningAmani Yehya, Fatima Ghamlouche, Sana Hachem, et al.
Cancer Drug Resistance (Alhambra, Calif.)|September 30, 2022
Drug resistance in metastatic castration-resistant prostate cancer: an update on the status quoAmani Yehya, Fatima Ghamlouche, Amin Zahwe, et al.
International Journal of Molecular Sciences|May 27, 2026
Integrated Phenotypic and Transcriptomic Profiling Positions ONC212 as a Lead Imipridone in Androgen-Independent Prostate Cancer ModelsFatima Ghamlouche, Amani Yehya, Abdallah Kurdi, et al.
World Journal of Clinical Oncology|January 2, 2026
Liquid biopsy in genitourinary cancers: Diagnostic and prognostic implicationsJoe Youssef, Amani Yehya, Zahraa Salhab, et al.
Frontiers in Cell and Developmental Biology|July 16, 2025
Repurposing piroxicam enhances the antineoplastic effects of docetaxel and enzalutamide in prostate cancer cells using 2D and 3D <i>in vitro</i> culture modelsAmani Yehya, Fatima Ghamlouche, Raed Karami, et al.
Translational Oncology|January 6, 2023
MicroRNAs as clinical tools for diagnosis, prognosis, and therapy in prostate cancerFatima Ghamlouche, Amani Yehya, Yousef Zeid, et al.
Pharmacological Reports : PR|November 17, 2024
ONC206, an imipridone derivative, demonstrates anti-colorectal cancer activity against stem/progenitor cells in 3D cell cultures and in patient-derived organoidsAlissar Monzer, Fatima Ghamlouche, Kevork Wakimian, et al.
Pageof 1